283 related articles for article (PubMed ID: 25048786)
1. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Gribben JG
Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
[TBL] [Abstract][Full Text] [Related]
2. Immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Ramsay AG; Gribben JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):13-20. PubMed ID: 22231031
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies including transplantation: eradication of disease.
Gribben JG; Riches JC
Hematology Am Soc Hematol Educ Program; 2013; 2013():151-7. PubMed ID: 24319176
[TBL] [Abstract][Full Text] [Related]
6. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Lapalombella R; Gowda A; Joshi T; Mehter N; Cheney C; Lehman A; Chen CS; Johnson AJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
Br J Haematol; 2009 Mar; 144(6):848-55. PubMed ID: 19183192
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
8. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P; Delgado J
Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Molica S
Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
12. Novel agents for chronic lymphocytic leukemia.
Wu M; Akinleye A; Zhu X
J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Freeman CL; Gribben JG
Curr Hematol Malig Rep; 2016 Feb; 11(1):29-36. PubMed ID: 26857283
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
15. Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
Riches JC; Ramsay AG; Gribben JG
Curr Pharm Des; 2012; 18(23):3389-98. PubMed ID: 22591385
[TBL] [Abstract][Full Text] [Related]
16. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
17. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
